INDIAN PATENT REGIME: IN RE EVERGREENING
International Journal of Legal Studies and Research · 08.03.2026 · 11 (2)
DOI: 10.69953/ijlsr.v11i2.859 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Legal Studies and Research, online erschienen am 08.03.2026. Verfasst von Debby Jain. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Patents reward novel inventions of industrial application and offer market exclusivity to patentees for 20 years, subject to municipal laws that delineate the scope of protection. However, innovators may sometimes fail to maximize profits in the statutory term and attempt evergreening, which is particularly popular in the pharma sector and often targeted at delaying entry of generics. Resultantly, it is viewed as anti-competitive and prohibited in public interest. In India, § 3(d), Patents Act, 1970 prohibits evergreening and the decision in Novartis v. UOI has become the holy grail for authorities to examine patent applications. Given its fact-specific nature and a hint of fallibility, it is unclear how diverse issues are being decided today based on law laid down in this decision. Viewed in the backdrop of poor public expenditure on health and R&D, resolution of these issues assumes paramount importance.
Zitieren
APA
Jain, D. (2026). INDIAN PATENT REGIME: IN RE EVERGREENING. International Journal of Legal Studies and Research, 11(2). https://doi.org/10.69953/ijlsr.v11i2.859
Vancouver
Jain D. INDIAN PATENT REGIME: IN RE EVERGREENING. International Journal of Legal Studies and Research. 2026;11(2). doi:10.69953/ijlsr.v11i2.859
BibTeX
@article{Jain2026,
author = {Jain, Debby},
title = {INDIAN PATENT REGIME: IN RE EVERGREENING},
journal = {International Journal of Legal Studies and Research},
year = {2026},
volume = {11},
number = {2},
doi = {10.69953/ijlsr.v11i2.859}
}
EUVIMED